Aligos Therapeutics
ALGS
57 hedge funds and large institutions have $550M invested in Aligos Therapeutics in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 9 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
10% more funds holding
Funds holding: 52 → 57 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less ownership
Funds ownership: 2.83% → 2.83% (-0%)
10% less capital invested
Capital invested by funds: $612M → $550M (-$62.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.4M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$5.46M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.49M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$24.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.22M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.73M |
| 4 |
Millennium Management
New York
|
-$741K |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$548K |
ALGS Hedge Fund Activity: Q2 2021 in Review
57 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q2 2021, worth a combined $550M — down 10% from $612M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ALGS positions and 9 closed out — a net gain of 5 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $9.9M. The largest seller was Versant Venture Management, cutting an estimated $24.8M.
- 57 institutional investors held Aligos Therapeutics (ALGS) as of Q2 2021, up from 52 in Q1 2021.
- Funds reported $550M of Aligos Therapeutics stock for Q2 2021, down 10% quarter-over-quarter.
- 14 funds opened new Aligos Therapeutics positions in Q2 2021 and 9 closed out, a net change of +5 holders.
- The largest Aligos Therapeutics buyer in Q2 2021 was BlackRock, an estimated $9.9M added.
- The largest Aligos Therapeutics seller in Q2 2021 was Versant Venture Management, an estimated $24.8M sold.
Based on aggregated 13F filings for Q2 2021.